FOXO1 inhibits osteosarcoma oncogenesis via Wntβ-catenin pathway suppression

Oncogenesis

Volumn 4, Issue , 2015, Pages

  Guan, H ^a   Tan, P ^a   Xie, L ^a   Mi, B ^a   Fang, Z ^a   Li, J ^a   Yue, J ^b   Liao, H ^a   Li, F ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; TRANSCRIPTION FACTOR FKHR; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; COLONY FORMATION; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; GENE TARGETING; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OSTEOSARCOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WHOLE GENOME SEQUENCING;

EID: 84941061222     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2015.25     Document Type: Article

References (47)

1. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008; 466: 2114-2130.
2. Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N, Committee CBT. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer 2013; 60: 1009-1015.
3. Vijayakumar S, Liu G, Rus IA, Yao S, Chen Y, Akiri G et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell 2011; 19: 601-612.
4. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002; 102: 338-342.
5. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 2003; 20: 525-529.
6. Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA et al. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 2013; 13: 245.
7. Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 2011; 117: 4925-4938.
8. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6: 572-577.
9. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008; 112: 2119-2129.
10. Essaghir A, Dif N, Marbehant CY, Coffer PJ, Demoulin JB. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem 2009; 284: 10334-10342.
11. Iyer S, Ambrogini E, Bartell SM, Han L, Roberson PK, de Cabo R et al. FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest 2013; 123: 3409-3419.
12. Tan Q, Soerensen M, Kruse TA, Christensen K, Christiansen L. A novel permutation test for case-only analysis identifies epistatic effects on human longevity in the FOXO gene family. Aging Cell 2013; 12: 690-694.
13. Soerensen M, Dato S, Christensen K, McGue M, Stevnsner T, Bohr VA et al. Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data. Aging Cell 2010; 9: 1010-1017.
14. Peck B, Ferber EC, Schulze A. Antagonism between FOXO and MYC regulates cellular powerhouse. Front Oncol 2013; 3: 96.
15. Jensen KS, Binderup T, Jensen KT, Therkelsen I, Borup R, Nilsson E et al. FoxO3A promotes metabolic adaptation to hypoxia by antagonizing Myc function. EMBO J 2011; 30: 4554-4570.
16. Ferber EC, Peck B, Delpuech O, Bell GP, East P, Schulze A. FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ 2012; 19: 968-979.
17. Rached MT, Kode A, Xu L, Yoshikawa Y, Paik JH, Depinho RA et al. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab 2010; 11: 147-160.
18. Kousteni S. FoxO1: a molecule for all seasons. J Bone Miner Res 2011; 26: 912-917.
19. Kousteni S. FoxO1, the transcriptional chief of staff of energy metabolism. Bone 2012; 50: 437-443.
20. Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L et al. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab 2010; 11: 136-146.
21. Rached MT, Kode A, Silva BC, Jung DY, Gray S, Ong H et al. FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest 2010; 120: 357-368.
22. Kim KM, Park SJ, Jung SH, Kim EJ, Jogeswar G, Ajita J et al. miR-182 is a negative regulator of osteoblast proliferation, differentiation, and skeletogenesis through targeting FoxO1. J Bone Miner Res 2012; 27: 1669-1679.
23. Chang YW, Zhao YF, Cao YL, Gu XF, Li ZQ, Wang SQ et al. Liver X receptor alpha inhibits osteosarcoma cell proliferation through up-regulation of FoxO1. Cell Physiol Biochem 2013; 32: 180-186.
24. Jin S, Pang RP, Shen JN, Huang G, Wang J, Zhou JG. Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis 2007; 12: 1317-1326.
25. Pei H, Jin Z, Chen S, Sun X, Yu J, Guo W. MiR-135b promotes proliferation and invasion of osteosarcoma cells via targeting FOXO1. Mol Cell Biochem 2015; 400: 245-252.
26. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005; 65: 9226-9235.
27. Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M et al. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosomes Cancer 2009; 48: 679-693.
28. Ozaki T, Schaefer KL, Wai D, Buerger H, Flege S, Lindner N et al. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 2002; 102: 355-365.
29. Sadikovic B, Park PC, Selvarajah S, Zielenska M. Array comparative genomic hybridization in osteosarcoma. Methods Mol Biol 2013; 973: 227-247.
30. Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 2014; 7: 104-112.
31. Xie L, Ushmorov A, Leithauser F, Guan H, Steidl C, Farbinger J et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood 2012; 119: 3503-3511.
32. Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A et al. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol 2010; 78: 961-970.
33. Zhang H, Fang J, Yao D, Wu Y, Ip C, Dong Y. Activation of FOXO1 is critical for the anticancer effect of methylseleninic acid in prostate cancer cells. Prostate 2010; 70: 1265-1273.
34. Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A et al. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene 2014; 33: 3927-3938.
35. Magro G, Righi A, Casorzo L, Antonietta T, Salvatorelli L, Kacerovska D et al. Mammary and vaginal myofibroblastomas are genetically related lesions: fluorescence in situ hybridization analysis shows deletion of 13q14 region. Hum Pathol 2012; 43: 1887-1893.
36. Maggiani F, Debiec-Rychter M, Verbeeck G, Sciot R. Extramammary myofibroblastoma is genetically related to spindle cell lipoma. Virchows Arch 2006; 449: 244-247.
37. Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX et al. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 2006; 66: 6998-7006.
38. Xie L, Ritz O, Leithauser F, Guan H, Farbinger J, Weitzer CD et al. FOXO1 down-regulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma. Oncotarget 2014; 5: 5392-5402.
39. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007; 128: 325-339.
40. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011; 146: 697-708.
41. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007; 128: 309-323.
42. Siqueira MF, Flowers S, Bhattacharya R, Faibish D, Behl Y, Kotton DN et al. FOXO1 modulates osteoblast differentiation. Bone 2011; 48: 1043-1051.
43. Huber MA, Denk A, Peter RU, Weber L, Kraut N, Wirth T. The IKK-2/Ikappa Balpha/NF-kappa B pathway plays a key role in the regulation of CCR3 and eotaxin-1 in fibroblasts. A critical link to dermatitis in Ikappa Balpha-deficient mice. J Biol Chem 2002; 277: 1268-1275.
44. Southgate RJ, Neill B, Prelovsek O, El-Osta A, Kamei Y, Miura S et al. FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle. J Biol Chem 2007; 282: 21176-21186.
45. Guan H, Xie L, Klapproth K, Weitzer CD, Wirth T, Ushmorov A. Decitabine represses translocated MYC oncogene in Burkitt lymphoma. J Pathol 2013; 229: 775-783.
46. Guan H, Xie L, Leithauser F, Flossbach L, Moller P, Wirth T et al. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood 2010; 116: 1469-1478.
47. Guan H, Zhao L, Cao H, Chen A, Xiao J. Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss. FASEB J 2015; 29: 1092-1101.